S1B

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

Retrieved on: 
Thursday, January 25, 2024
Science, Software, Other Science, Biotechnology, Research, Health, Data Management, Technology, The three Rs, Database, Life, S1B, Workflow, Drug discovery, Woe, ICH, Organization, Guideline, Patient safety, Literature, Growth, Pharmaceutical industry

Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum .

Key Points: 
  • Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum .
  • The ICH S1B guideline has introduced a WoE approach to assess human carcinogenic potential of small molecule pharmaceuticals and determine whether a 2-year rat carcinogenicity study would add value.
  • Application of this integrated analysis supports the 3Rs principles, while promoting safe and ethical development of new small molecule pharmaceuticals.
  • Since that time, Instem’s team of in silico experts have been instrumental in driving forward a solution to support the S1B guideline.